Correlation between plasma TAFI levels and risk of RSA
Table 4 shows the correlations between plasma TAFI levels explored in
the binary logistic regression model and the risk of RSA. The total
population was divided into three groups according to the normal range
of plasma TAFI levels: normal levels of plasma TAFI were defined as
24-35ug/ml, TAFI<24ug/mL, TAFI>35ug/mL. The adjusted covariates for
each group were the variables that were statistically significant by
logistic regression. Compared with TAFI levels of 24-35ug/ml. In the
Anti-TPO positive group, the risk of RSA was significantly increased in
those with TAFI <24 (OR, 2.15; 95% CI, 1.221-3.785; P=0.008).
This result was also seen in the Anti-TPO negative group and the Anti-TG
positive group. In the Anti-TPO negative group, the risk of RSA was
increased in those with TAFI <24 (OR, 1.429; 95% CI,
1.032-1.98; P=0.032); in the Anti-TG positive group, the risk of RSA was
significantly increased in those with TAFI <24 (OR, 2.215;
95% CI, 1.265-3.878; P=0.005). It is important to note that in the
Anti-TPO negative group, the OR for the increased risk of RSA in the
TAFI <24 population was smaller than in the two-positive
group.
As shown in Fig1, the multivariate adjusted spline regression model
showed a linear negative dose response relationship between TAFI and RSA
in all subgroups, with P values for nonlinearity all greater than 0.05.
Of note, in the two positive subgroups, OR value was approximately less
than 1 when TAFI levels were within the normal reference range of 24-35
ug/mL. However, when TAFI levels were below 24 ug/mL, the OR value
increased and was higher than that in the two negative subgroups. On the
other hand, when TAFI levels were above 35 ug/mL, an increasing TAFI
level was found to be associated with a higher risk of RSA, but the
trend is not obvious. This trend was not observed in the two negative
subgroups.